Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,993.17
    +742.66 (+1.45%)
     

  • CMC Crypto 200

    1,387.91
    +75.29 (+5.74%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

VBI Vaccines signs agreement with Canada to develop COVID-19 vaccine by 2022

Reuters
·1-min read

(Reuters) - VBI Vaccines Inc <VBIV.O> said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.

Canada will contribute around 75% of the U.S.-based company's development costs and C$55.9 million (32.84 million pounds) for the project.

VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.

As per the agreement, signed last week, the company's Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.

There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel)